LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Search

Quidel Corp

Uždarymo kaina

11.05 -0.72

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.76

Max

11.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

39M

-92M

Pardavimai

-104M

620M

Pelno marža

-14.811

Darbuotojai

6,500

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+8.18% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-140M

560M

Ankstesnė atidarymo kaina

11.77

Ankstesnė uždarymo kaina

11.05

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 22:54; UTC

Uždarbis

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026-05-13 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-13 23:51; UTC

Rinkos pokalbiai

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-13 23:17; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-13 23:16; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026-05-13 23:15; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026-05-13 23:14; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026-05-13 23:02; UTC

Rinkos pokalbiai
Uždarbis

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026-05-13 22:59; UTC

Rinkos pokalbiai
Uždarbis

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026-05-13 22:24; UTC

Uždarbis

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Revenue Growth 47%>XRO.AU

2026-05-13 22:22; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026-05-13 22:18; UTC

Uždarbis

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026-05-13 22:16; UTC

Uždarbis

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026-05-13 22:13; UTC

Uždarbis

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026-05-13 22:12; UTC

Uždarbis

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026-05-13 22:09; UTC

Uždarbis

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026-05-13 22:00; UTC

Uždarbis

Cisco to Shed Jobs for All-In AI Push -- Update

2026-05-13 21:11; UTC

Uždarbis

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

8.18% į viršų

12 mėnesių prognozė

Vidutinis 12.03 USD  8.18%

Aukščiausias 13 USD

Žemiausias 11 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

6 ratings

1

Pirkti

4

Laikyti

1

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

Veiklos pelnas

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat